[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100435571":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":24,"interventions":31,"overallOfficials":37,"centralContacts":42,"locations":52,"responsibleParty":71,"collaborators":17,"id":74,"slug":17,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":17,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":17,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":17,"overallStatus":54,"whyStopped":17,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"ORR","Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects","1 year",[14],{"measure":15,"description":16,"timeFrame":12},"PFS","Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE",[25],{"label":26,"type":27,"description":28,"interventionNames":29},"Arm A","EXPERIMENTAL","Treatment arm",[30],"Drug: JS201 combine with Lenvatinib",[32],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":17},"DRUG","JS201 combine with Lenvatinib","JS201 300mg i.v Q2wLenvatinib 8mg po. Qd",[26],[38],{"name":39,"affiliation":40,"role":41},"Yongchang Zhang, MD","Hunan Cancer Hospital","PRINCIPAL_INVESTIGATOR",[43,48],{"name":39,"role":44,"phone":45,"phoneExt":46,"email":47},"CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":49,"role":44,"phone":50,"phoneExt":45,"email":51},"Nong Yang, MD","+8613055193557","yangnong0217@163.com",[53],{"facility":40,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"RECRUITING","Changsha","Hunan","410013","China","CN",{"type":61,"coordinates":62},"Point",[63,64],112.97087,28.19874,{"lat":64,"lon":63},[67,69],{"name":49,"role":44,"phone":68,"phoneExt":17,"email":51},"+86 731 89762323",{"name":39,"role":44,"phone":70,"phoneExt":17,"email":47},"+86 731 89762321",{"type":41,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Yongchang Zhang","Director, Head of Medical Oncology, Principal Investigator, Clinical Professor","100435571",false,"NCT04951947","JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer","A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure","Inclusion Criteria:\n\n* 1\\. The imaging diagnosis is the extensive stage of SCLC\n* 2\\. The patient failed first-line EC+PD-L1 treatment\n* 3 PS 0-1\n\nExclusion Criteria:\n\n* 1\\. Diagnosed as non-small cell lung cancer\n* 2\\. Women during pregnancy\n* 3\\. Patients with symptomatic brain metastases\n* 4\\. PS≥2","ALL","18 Years","75 Years",{"count":84,"type":85},30,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.",[91],"Small-cell Lung Cancer","2024-09-17",{"date":94,"type":95},"2024-09-19","ACTUAL",{"date":97,"type":95},"2023-06-01",{"date":99,"type":85},"2025-06-01",{"name":5,"class":6},1]